Eyeworld

3 EW ASCRS NEWS August 2018 by Natalie Zundel ASCRS Foundation Development Director support from the ASCRS Founda- tion," said Stephen Lane, MD, co-chair of the ASCRS Foundation. "Together, we're working to end solution for Americans in need by enabling ASCRS member eye sur- geons to perform charitable cataract surgeries in their own communities with administrative and financial for the 3rd annual National Sight Week initiative are October 14–20. The goal is not only to increase the number of charitable cataract surger- ies, but to raise overall awareness of the Operation Sight program. Operation Sight is the ASCRS Foundation's domestic charita- ble cataract surgery program. The program assists uninsured U.S. patients who couldn't otherwise obtain cataract care on their own. By leveraging the combined strength of established charitable organizations along with ASCRS member volun- teer surgeons, Operation Sight pro- vides needed care to those unable to access or afford surgery. "The ASCRS Foundation's Operation Sight initiative offers a Week of October 14–20 draws attention to humanitarian eye care in the U.S. N ational Sight Week is a cel- ebration of volunteerism, during which members of the ASCRS Foundation's Operation Sight network are encouraged to contribute one or more charitable cataract surgeries in their own communities. The Foun- dation works to match needy, eligi- ble patients with volunteer surgeons, and provides a financial stipend for each surgery completed. The ASCRS Foundation is pleased to announce that the dates Announcing the 2018 National Sight Week © 2018 Novartis 2/18 US-CYP-18-E-0312 CYPASS ® ULTRA SYSTEM IMPORTANT PRODUCT INFORMATION CAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. INDICATION: The CYPASS ® Ultra System is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: Use of the CYPASS ® Ultra System is contraindicated in the following circumstances or conditions: (1) in eyes with angle closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle. MRI INFORMATION: The CYPASS ® Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non-magnetic polymer that poses no known hazards in all magnetic resonance imaging environments. WARNINGS: Gonioscopy should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the CYPASS ® Ultra System has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with significant prior trauma, chronic inflammation, eyes with an abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually significant cataract. The safety and effectiveness of use of more than a single CYPASS ® Micro-Stent has not been established. ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with the CYPASS ® Micro-Stent to cataract surgery alone, the most common post-operative adverse events included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for CYPASS ® vs. 15.3% for cataract surgery only); anterior chamber cell and flare requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual field mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%). ATTENTION: PLEASE REFER TO THE PRODUCT INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND ADVERSE EVENTS. 101881 US-CYP-18-E-0312_PI EW.indd 1 6/12/18 9:10 AM Volunteer Kristen Burwick, MD, with an Operation Sight patient post-surgery Source: Eye Surgeons of Nebraska continued on page 8 Staff at the Hamilton Eye Institute during its inaugural Cataract-A-Thon Source: Hamilton Eye Institute

• Cover